TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Advisory Support to Prolong the Breast-feeding Period Reduce the Risk for Obesity and Metabolic Dysfunction in Infants of Obese Mothers ?
Brief Summary: 0-hypothesis: advisory support does not

1. prolong the the breast-feeding period
2. minimize the risk of obesity and metabolic dysfunction in infants of obese mothers


Options:
A: Arm Label: advisory support; Type: EXPERIMENTAL; Interventions: Behavioral: advisory support | Intervention Type: BEHAVIORAL; Name: advisory support; Assigned to Arm(s): advisory support
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity; Type: OTHER; Interventions: Other: Telephone-based breastfeeding peer counseling | Arm Label: High Intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone-based breastfeeding peer counseling | Intervention Type: OTHER; Name: Telephone-based breastfeeding peer counseling; Assigned to Arm(s): High Intensity, Low Intensity
C: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Lactation Consultant | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Provider Prompt | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: LC+ Provider Prompt | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lactation Consultant; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Provider Prompt; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: LC+ Provider Prompt; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Advisory Support to Prolong the Breast-feeding Period Reduce the Risk for Obesity and Metabolic Dysfunction in Infants of Obese Mothers ?
Brief Summary: 0-hypothesis: advisory support does not

1. prolong the the breast-feeding period
2. minimize the risk of obesity and metabolic dysfunction in infants of obese mothers


Options:
A: Arm Label: advisory support; Type: EXPERIMENTAL; Interventions: Behavioral: advisory support | Intervention Type: BEHAVIORAL; Name: advisory support; Assigned to Arm(s): advisory support
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: EpxBreastfeeding, Other: Baby book survey | Arm Label: Control; Type: OTHER; Interventions: Other: Baby book survey | Intervention Type: OTHER; Name: EpxBreastfeeding; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Baby book survey; Assigned to Arm(s): Control, Intervention
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS reminder; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminder | Arm Label: SMS reminder + Unconditional Incentive; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminder, Behavioral: Unconditional Incentive | Intervention Type: BEHAVIORAL; Name: SMS reminder; Assigned to Arm(s): SMS reminder, SMS reminder + Unconditional Incentive | Intervention Type: BEHAVIORAL; Name: Unconditional Incentive; Assigned to Arm(s): SMS reminder + Unconditional Incentive

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease
Brief Summary: The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein \[hs-CRP\] and fecal calprotectin), and corticosteroid use, improves the rate of mucosal healing 48 weeks after randomization compared with management using less stringent criteria based only on CDAI and corticosteroid use.


Options:
A: Arm Label: Tight Control Management; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Arm Label: Clinically Driven Management; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Clinically Driven Management, Tight Control Management
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: control = conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immunossuppresive treatment; Type: EXPERIMENTAL; Interventions: Drug: early immunosuppressants (azathioprine, methotrexate) | Intervention Type: DRUG; Name: early immunosuppressants (azathioprine, methotrexate); Assigned to Arm(s): Immunossuppresive treatment
D: Arm Label: Adacolumn; Type: ACTIVE_COMPARATOR; Interventions: Device: Adacolumn | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Adacolumn; Assigned to Arm(s): Adacolumn | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease
Brief Summary: The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein \[hs-CRP\] and fecal calprotectin), and corticosteroid use, improves the rate of mucosal healing 48 weeks after randomization compared with management using less stringent criteria based only on CDAI and corticosteroid use.


Options:
A: Arm Label: Tight Control Management; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Arm Label: Clinically Driven Management; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Clinically Driven Management, Tight Control Management
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
C: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inpatient Technology-Supported Assisted Referral
Brief Summary: The goal of this patient-randomized effectiveness trial is to demonstrate that an inpatient technology-supported assisted referral (I-TSAR) and follow-up approach is an effective and cost-effective method to help hospitalized patients successfully quit smoking. The proposed study represents a unique opportunity to assess the effectiveness and cost-effectiveness of linking inpatient and outpatient delivery of smoking cessation services in two large and very different health care delivery systems. We will enroll 900 participants (600 intervention, 300 controls) over 15-months and collect follow-up survey and health care utilization data over 12 months to estimate: 1) smoking abstinence at 6 and 12 months for I-TSAR intervention recipients compared to usual care; 2) the dose effect on smoking abstinence at 6 and 12 months for I-TSAR recipients compared to usual care; 3) total and mean costs per participant for I-TSAR and usual care recipients, and, if effective, estimate the incremental cost-effectiveness of the intervention vs. controls at 12 months from health plan/insurer and societal perspectives; and 4) differences in health care utilization at 12 months for I-TSAR versus controls.


Options:
A: Arm Label: Telephone Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Counseling | Arm Label: Written Materials; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): Written Materials
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CBST | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + CBST; Assigned to Arm(s): 1
C: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
D: Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Feeback group | Intervention Type: BEHAVIORAL; Name: Feeback group; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inpatient Technology-Supported Assisted Referral
Brief Summary: The goal of this patient-randomized effectiveness trial is to demonstrate that an inpatient technology-supported assisted referral (I-TSAR) and follow-up approach is an effective and cost-effective method to help hospitalized patients successfully quit smoking. The proposed study represents a unique opportunity to assess the effectiveness and cost-effectiveness of linking inpatient and outpatient delivery of smoking cessation services in two large and very different health care delivery systems. We will enroll 900 participants (600 intervention, 300 controls) over 15-months and collect follow-up survey and health care utilization data over 12 months to estimate: 1) smoking abstinence at 6 and 12 months for I-TSAR intervention recipients compared to usual care; 2) the dose effect on smoking abstinence at 6 and 12 months for I-TSAR recipients compared to usual care; 3) total and mean costs per participant for I-TSAR and usual care recipients, and, if effective, estimate the incremental cost-effectiveness of the intervention vs. controls at 12 months from health plan/insurer and societal perspectives; and 4) differences in health care utilization at 12 months for I-TSAR versus controls.


Options:
A: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
B: Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: Standard Care | Arm Label: Sustained Care; Type: EXPERIMENTAL; Interventions: Behavioral: Sustained Care | Intervention Type: BEHAVIORAL; Name: Sustained Care; Assigned to Arm(s): Sustained Care | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard care
C: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
D: Arm Label: 1- Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 - Automated Mailing; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing | Arm Label: 3 - Automated Mailing Plus Assisted; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing Plus Assisted | Arm Label: 4 - Auto Plus Assisted Plus Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Auto Plus Assisted Plus Navigation | Intervention Type: BEHAVIORAL; Name: Automated Mailing; Assigned to Arm(s): 2 - Automated Mailing | Intervention Type: BEHAVIORAL; Name: Automated Mailing Plus Assisted; Assigned to Arm(s): 3 - Automated Mailing Plus Assisted | Intervention Type: BEHAVIORAL; Name: Auto Plus Assisted Plus Navigation; Assigned to Arm(s): 4 - Auto Plus Assisted Plus Navigation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Effects of Commuter Cycling
Brief Summary: The purpose of this study is to determine whether cycling to school is effective in the prevention of the metabolic syndrome.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cycling to school; Type: EXPERIMENTAL; Interventions: Behavioral: Cycling to school | Intervention Type: BEHAVIORAL; Name: Cycling to school; Assigned to Arm(s): Cycling to school
B: Arm Label: Healthy Buddies Curriculum; Type: EXPERIMENTAL; Interventions: Other: Healthy Buddies Curriculum | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Buddies Curriculum; Assigned to Arm(s): Healthy Buddies Curriculum
C: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Health education | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Carrier Guidance | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Carrier Guidance; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (1) Discontinuation of Lens Wear in Existing Ortho-k Children
Brief Summary: The primary aim of this study is to compare eyeball elongation in existing ortho-k subjects who stop the treatment with subjects who continue ortho-k lens wear and control subjects wearing single-vision glasses.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Arm Label: single-vision glasses and ortho-k lenses; Type: EXPERIMENTAL; Interventions: Device: ortho-k lenses, Device: single-vision glasses | Arm Label: ortho-k lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k lenses | Arm Label: single-vision glasses; Type: OTHER; Interventions: Device: single-vision glasses | Intervention Type: DEVICE; Name: ortho-k lenses; Assigned to Arm(s): ortho-k lenses, single-vision glasses and ortho-k lenses | Intervention Type: DEVICE; Name: single-vision glasses; Assigned to Arm(s): single-vision glasses, single-vision glasses and ortho-k lenses
C: Arm Label: Intervention Group (Atropine 0.01%); Type: EXPERIMENTAL; Interventions: Drug: Atropine Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Atropine Sulfate; Assigned to Arm(s): Intervention Group (Atropine 0.01%) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: single vision soft contact lens; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Defocus Incorporated Soft Contact (DISC) lens; Type: EXPERIMENTAL; Interventions: Device: Defocus Incorporated Soft Contact (DISC) lens | Intervention Type: DEVICE; Name: Defocus Incorporated Soft Contact (DISC) lens; Assigned to Arm(s): Defocus Incorporated Soft Contact (DISC) lens

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes
Brief Summary: The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation.


Options:
A: Arm Label: Pentoxifylline; Type: EXPERIMENTAL; Interventions: Drug: Pentoxifylline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pentoxifylline; Assigned to Arm(s): Pentoxifylline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5093151 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5093151; Assigned to Arm(s): 1
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exenatide in Extreme Pediatric Obesity
Brief Summary: Extreme pediatric obesity, the fastest growing category of obesity in youth, is associated with high risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2DM). Obesity tracks strongly into adulthood and interventions early in life may reduce risk for developing cardiovascular disease and type 2 diabetes. Few drug therapies for weight loss have been evaluated in adolescents. Since exenatide is associated with weight loss and improves risk factors for cardiovascular disease and type 2 diabetes in adults, it may be useful in extremely obese youth. Our primary objective in this study is to generate preliminary data on the ability of exenatide to reduce body mass index (BMI) and improve risk factors for cardiovascular disease and type 2 diabetes in 26 extremely obese adolescents (age 12-19 years) in a three-month, randomized, double-blind, placebo-controlled pilot clinical trial. GLP-1 therapy has never been evaluated as a treatment for pediatric obesity and is an innovative approach to a challenging and significant health care problem.


Options:
A: Arm Label: Diet/Exercise only, then Diet/Exercise plus Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Arm Label: Diet/Exercise plus Metformin, then Diet/Exercise only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Dietary modification with caloric restriction; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Establishment of exercise protocol; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only
B: Arm Label: Exenatide, then Open-Label Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo, then Open Label Exenatide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide, then Open-Label Exenatide, Placebo, then Open Label Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, then Open Label Exenatide
C: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide
D: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol

Answer: B